OncoBLAZE
Reimagining Precision Cancer Therapy
Our Mission
At OncoBLAZE, our mission is to pioneer cutting-edge technologies that precisely target and eliminate residual cancer cells after surgery. We are dedicated to enhancing patient outcomes by preventing cancer recurrence and advancing our personalized treatment solution. Through relentless innovation and strategic collaborations, we are committed to saving cancer patients' lives while reducing the economic burden of cancer care.
The Problem: Cancer Recurrence
Cancer recurrence refers to the return of cancer following treatment after a period of remission or apparent eradication. It indicates that cancer cells have survived initial treatment and have begun to grow again, potentially in the same location or elsewhere in the body. OncoBLAZE technology focuses on eradicating remnant cancer cells after surgical tumor removal, to prevent recurrence.
There are annually about 20 million new cancer cases worldwide, and 2 million new cases in the US. Cancer recurrences not only impact individuals and their families, but also pose a substantial economic burden due to costly follow-up therapies and increased healthcare utilization. Despite the efficacy of surgery in many cancers, certain cancer types such as soft tissue sarcoma and certain oral cavity cancers present unique challenges in achieving complete eradication of malignant cells during surgery. Consequently, residual cancer cells pose a persistent risk of recurrence in these cancers.
Our Technology
Chemotherapy agents are highly toxic drugs, and when conventional chemotherapy is administered, only a tiny fraction (<0.1%) goes to the targeted cancer cells. Most of the chemo drugs end up in normal organs and tissues, causing unintended damage and both short- and long-term side effects. Our technology enables the precise delivery of chemo drugs to the cancer cells. We achieve up to 20-30 times higher drug delivery to cancer cells compared to conventional chemotherapy.
We apply this precise chemo drug delivery approach towards cancer cells that are remnant after surgical tumor excision. After surgery, triggered nanoparticles (TNP) encapsulating a chemotherapeutic drug are administered to the patient and distributed throughout the body. As long as the chemo drug remains encapsulated in these TNP, it remains non-toxic and does not exert it’s cell-killing effects. The precise release of the chemotherapy is facilitated by precision delivery of electromagnetic energy to the tissue region harboring remnant cancer cells. In the tissue region where this release is triggered, a large chemotherapy dose is delivered that eliminates the remnant cancer cells.
OncoBLAZE PRECISION THERAPY AFTER SURGERY
Proprietary Imaging Technology Visualizes Drug Delivery
We developed imaging technology that can visualize drug released from TNP during heating. This enables the physician to deliver drug precisely to the tissue where remnant cancer cells are, and to ensure adequate drug is delivered to kill all cancer cells.
Heat is precisely targeted to a portion of a the surgical cavity where a tumor has been removed, and where remnant cancer cells are anticipated. The amount of drug delivered to the heated tissue is visualized while heat is applied.
By leveraging triggered nanoparticles (TNP) and precision targeting of electromagnetic radiation that triggers chemotherapy release from TNP, we seek to improve outcomes for cancer patients, particularly in cases where traditional methods are insufficient. Our mission is to contribute to the evolution of cancer care, offering promising solutions that address unmet needs in the field. Join us as we work towards a future with improved treatment options for those affected by cancer.
